Full Text View
Tabular View
Study Results
Related Studies
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
This study is ongoing, but not recruiting participants.
Study NCT01102972   Information provided by ViiV Healthcare

First Received on April 8, 2010.   Last Updated on January 24, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
More general conditions related to this trial
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Reyataz + Norvir + Truvada
Reyataz + Epzicom
Additional drug interventions recognized in this trial
Atazanavir
Emtricitabine
Tenofovir
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
HIV Protease Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Protease Inhibitors
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
ViiV Healthcare
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services